Impact ledger
IQVIA Holdings Inc. (IQV): the developments shaping its investment case
Follow the evidence affecting IQVIA Holdings Inc.'s financing assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-06-12 | wacc | Bearish | IG cost of debt is below blended cost of capital; weighting effect lowers WACC. |
| 2026-06-12 | interest_expense | Bullish | New IG coupon adds to recurring interest expense. |
| 2026-06-12 | net_debt | Bullish | Investment-grade issuance adds gross debt to the balance sheet. |
Event impact log
5 events mapped to IQV since 2026-09-03. Evidence through 2026-09-03.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M | Increased competition in the early-phase clinical research organization (CRO) market, potentially impacting pricing power or market share for established players. | watch | 3-12m | 0.30 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M | Slightly increased competitive pressure in the broader CRO market, particularly in early-phase services, as Fortrea expands its capabilities. | watch | 3-12m | 0.20 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M | Increased competitive pressure in the contract research organization (CRO) market as Fortrea expands its early-phase capabilities. However, the overall market remains large. | mixed | 3-12m | 0.20 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million | Increased competition in the early-phase clinical research organization (CRO) market from an expanded Fortrea, potentially impacting market share or pricing power. | mixed | 3-12m | 0.30 |
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million | Increased competitive pressure in the contract research organization (CRO) market, particularly in early-phase services. | mixed | 3-12m | 0.20 |
Continue this research
Build your IQVIA Holdings Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the IQV entity page →